Case number IPR2017-01095
Celltrion Inc. v. Biogen, Inc. > Documents
| Date Field | Doc. No. | Party | Description |
|---|---|---|---|
| Dec 4, 2018 | 61 | Patent Owner Biogen, Inc.'s Notice of Appeal Download | |
| Oct 4, 2018 | 60 | Termination Decision Document Download | |
| Sep 25, 2018 | 59 | Hearing Transcript Download | |
| Aug 24, 2018 | 56 | Patent Owner's Objections to Petitioner's Demonstratives Download | |
| Aug 24, 2018 | 55 | Patent Owner's Motion to Accept Objections to Petitioner's Demonstratives on August 17, 2018 Download | |
| Aug 24, 2018 | 57 | Petitioner's Objections to Patent Owner's Demonstrative Exhibit Download | |
| Aug 24, 2018 | 58 | Petitioner's Motion to Accept Objections to Patent Owner's Demonstratives on August 17, 2018 Download | |
| Aug 2, 2018 | 54 | Petitioner's Authorized Response to Patent Owner's Statement Regarding Petitioner's Reply Download | |
| Aug 1, 2018 | 53 | Order - 37 C.F.R. 42.70 Download | |
| Jul 26, 2018 | 52 | Patent Owner's Statement Regarding Petitioner's Reply Arguments and Evidence Beyond the Proper Scope Download | |
| Jul 19, 2018 | 51 | Petitioner's Request for Oral Hearing Download | |
| Jul 19, 2018 | 50 | Patent Owner's Request for Oral Argument Download | |
| Jul 12, 2018 | 49 | Patent Owner's Objections to Evidence Under 37 C.F.R. 42.64 Download | |
| Jul 5, 2018 | 1306 | Online Computer Library Center's ("OCLC") Connexion database record of Ex. 1304, Foon, K.A. & Fisher, R.I., Chapter 111: Lymphomas, in Williams Hematology, Fifth Edition, etc. Download | |
| Jul 5, 2018 | 1310 | Czuczman et al., IDEC-C2B8 and CHOP Chemoimmunotherapy of Low-Grade Lymphoma, Blood, 86(10, Suppl. 1):55a (Abstract 206) (Nov. 15, 1995) Download | |
| Jul 5, 2018 | 1324 | Patent Owner's Preliminary Response, Celltrion Inc. v. Biogen Inc., IPR2017-01094, Paper No. 10 (PTAB July 5, 2017) Download | |
| Jul 5, 2018 | 1325 | Foon, K.A. & Fisher R. I., Chapter 111: Lymphomas, in Williams Hematology, Fifth Edition, etc. (Date Stamped Second Copy) Download | |
| Jul 5, 2018 | 1313 | Marcus, et al., CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, 105(4):1417-1423 (Feb. 15, 2005) Download | |
| Jul 5, 2018 | 48 | Petitioner's Update Exhibit List Download | |
| Jul 5, 2018 | 1305 | Machine-Readable Cataloging ("MARC") record of Ex. 1304, Foon K.A. & Fisher, R.I., Chapter 111: in Williams Hematology, Fifth Edition, etc. Download | |
| Jul 5, 2018 | 1317 | Important Information About EDGAR page from Internet Archive Download | |
| Jul 5, 2018 | 1314 | MARC record of Ex. 1313, Marcus et al., CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, etc. Download | |
| Jul 5, 2018 | 1203 | McLaughlin et al., Stage 1-11 low-grade lymphomas: A prospective trial of combination chemotherapy and radiotherapy, Ann. Oncol., 2(Suppl. 2):137-140 (1991) Download | |
| Jul 5, 2018 | 1323 | Affidavit of Christopher Butler Download | |
| Jul 5, 2018 | 1312 | OCLC record of Ex. 1310, Czuczman et al., IDEC-C2B8 and CHOP Chemoimmunotherapy of Low-Grade Lymphoma, etc. Download | |
| Jul 5, 2018 | 1301 | McLaughlin et al., Stage 1-11 low-grade lymphomas: A prospective trial of combination chemotherapy and radiotherapy, Ann. Oncol., 2(Suppl. 2):137-140 (1991) Download | |
| Jul 5, 2018 | 47 | Petitioner's Combined Reply ISO Its Petition for Inter Partes Review Download | |
| Jul 5, 2018 | 1303 | Declaration of Sylvia Hall-Ellis Ph.D. ISO Petitioner's Reply Download | |
| Jul 5, 2018 | 1302 | McLaughlin et al., Pivotal Phase III Clinical Trial (PII CT) of the Chimeric Anti-CD20 Antibody (MAB) IDEC-C2B8 etc. Download | |
| Jul 5, 2018 | 1318 | General Information on the EDGAR Database page from Internet Archive Download | |
| Jul 5, 2018 | 1321 | EDGAR Filing Details Download | |
| Jul 5, 2018 | 1315 | OCLC record of Ex. 1313, Marcus et al., CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, etc. Download | |
| Jul 5, 2018 | 1311 | MARC record of Ex. 1310, Czuczman, et al., IDEC-C2B8 and CHOP Chemoimmunotherapy of Low-Grade Lymphoma, etc. Download | |
| Jul 5, 2018 | 1307 | Dana et al., Long-Term Follow-Up of Patients with Low-Grade Malignant Lymphomas Treated With Doxorubicin-Based Chemotherapy or Chemoimmunotherapy, etc. Download | |
| Jul 5, 2018 | 1304 | Foon, K.A. & Fisher, R. I., Chapter 111: Lymphomas, in Williams Hematology, Fifth Edition, etc. Download | |
| Jul 5, 2018 | 1319 | Search the EDGAR database page from Internet Archive Download | |
| Jul 5, 2018 | 1322 | 10-K/A .txt file from EDGAR system Download | |
| Jul 5, 2018 | 1309 | OCLC record of Ex. 1307, Dana et al., Long-Term Follow-Up of Patients with Low-Grade Malignant Lymphomas Treated with, etc. Download | |
| Jul 5, 2018 | 1316 | Edgar Database page from Internet Archive Download | |
| Jul 5, 2018 | 1320 | EDGAR Form Pick, Customized Forms Selection page from Internet Archive Download | |
| Jul 5, 2018 | 1300 | Declaration of Daniel J. Knauss ISO Petitioner's Combined Reply Download | |
| Jul 5, 2018 | 1308 | MARC record of Exhibit 1307, Dana et al., Long-Term Follow-Up of Patents with Low-Grade Malignant Lymphomas, etc. Download | |
| Jun 6, 2018 | 44 | Joint Stipulation to Modify Due Date 4B Download | |
| Jun 6, 2018 | 2031 | EX2031 - Declaration of Ann Simpson Download | |
| Jun 6, 2018 | 46 | Patent Owner's Supplemental Response Download | |
| Jun 6, 2018 | 2030 | EX2030 - Deposition Transcript of Patent Owner¿¿¿s Expert Peter McLaughlin, M.D. dated April 18, 2018 Download | |
| Jun 6, 2018 | 45 | Notice of Deposition of Izidore Lossos, M.D. Download | |
| Jun 6, 2018 | 2032 | EX2032 - USPTO, Guidance on the Impact of SAS on AIA Trial Proceedings, dated April 26, 2018 Download | |
| May 16, 2018 | 43 | Joint Stipulation to Modify Due Dates 4 and 5 Download | |
| May 11, 2018 | 42 | Modifying Scheduling Order Download | |
| May 7, 2018 | 40 | Order Conduct of Proceeding Download | |
| May 7, 2018 | 41 | Modified Scheduling Order Download | |
| Apr 30, 2018 | 39 | Conduct of the Proceeding - 37 C.F.R. 42.5 Download | |
| Apr 18, 2018 | 38 | Patent Owners Mandatory Notice Updating Related Matters Download | |
| Apr 18, 2018 | 37 | ORDER Conduct of Proceeding 37 C.F.R. §§ 42.5, 42.53(a) Download | |
| Apr 17, 2018 | 36 | Petitioner's Updated Mandatory Notice Updating Related Matters Download | |
| Mar 28, 2018 | 33 | Notice of Deposition of Dr. Peter McLaughlin Download | |
| Mar 28, 2018 | 34 | Scheduling Stipulation Resetting Due Dates 4 and 5 Download | |
| Mar 28, 2018 | 35 | Petitioner's Updated Mandatory Notice Replacing First Backup Counsel Download | |
| Feb 16, 2018 | 32 | Petitioner's Updated Certificate of Service of Petitioner's Objections to Patent Owner's Evidence Download | |
| Feb 14, 2018 | 31 | Petitioner's Objections to Patent Owner's Evidence Download | |
| Feb 7, 2018 | 2027 | EX 2027 - Lossos Depo Download | |
| Feb 7, 2018 | 30 | Patent Owner Response Download | |
| Feb 7, 2018 | 2025 | EX 2025 - Peterson Download | |
| Feb 7, 2018 | 2021 | EX 2021 - Gribben Download | |
| Feb 7, 2018 | 2015 | EX 2015 - Rituxan Label Download | |
| Feb 7, 2018 | 2013 | EX 2013 - Lopez-Guillermo Download | |
| Feb 7, 2018 | 2019 | EX 2019 - Smalley Download | |
| Feb 7, 2018 | 2024 | EX 2024 - Hagenbeek Download | |
| Feb 7, 2018 | 2018 | EX 2018 - McLaughlin (1992) Download | |
| Feb 7, 2018 | 2014 | EX 2014 - Rigacci Download | |
| Feb 7, 2018 | 2016 | EX 2016 - Megan Raymond's Declaration Download | |
| Feb 7, 2018 | 2017 | EX 2017 - Fisher Download | |
| Feb 7, 2018 | 2029 | EX 2029 - Expert Declaration McLaughlin Download | |
| Feb 7, 2018 | 2020 | EX 2020 - Han Download | |
| Feb 7, 2018 | 2028 | EX 2028 - Korsmeyer Download | |
| Feb 7, 2018 | 2026 | EX 2026 - McLaughlin (1987) Download | |
| Feb 7, 2018 | 2022 | EX 2022 - Raphael Download | |
| Feb 7, 2018 | 2023 | EX 2023 - Ezdinli Download | |
| Jan 24, 2018 | 29 | Modifying Scheduling Order Download | |
| Jan 11, 2018 | 27 | Decision Granting Unopposed Motion for Pro Hac Vice Admission of Mr. David Gindler Download | |
| Jan 11, 2018 | 28 | Notice of Deposition of Walter L. Longo, M.D. Download | |
| Jan 10, 2018 | 26 | Notice of Deposition of Izidore Lossos, M.D. Download | |
| Jan 2, 2018 | 25 | Decision - Denying Petitioner's Request for Rehearing Download | |
| Dec 22, 2017 | 24 | Supplemental Mandatory Notice Download | |
| Dec 22, 2017 | 23 | Power of Attorney Download | |
| Dec 8, 2017 | 22 | Scheduling Stipulation Resetting Due Dates 1 and 2 Download | |
| Nov 7, 2017 | 21 | Petitioner's Updated Exhibit List Download | |
| Nov 3, 2017 | 19 | Petitioner's Service of Supplemental Evidence Download | |
| Nov 3, 2017 | 20 | Petitioner's Updated Exhibit List Download | |
| Oct 26, 2017 | 18 | Motion to Appear Pro Hac Vice (Gindler) Download | |
| Oct 26, 2017 | 2012 | Ex 2012 Gindler PHV Declaration Download | |
| Oct 25, 2017 | 17 | Petitioner's Updated Mandatory Notice re Additional Backup Counsel Download | |
| Oct 25, 2017 | 16 | Petitioner's Updated Power of Attorney Appointing Additional Backup Counsel Download | |
| Oct 20, 2017 | 15 | Patent Owner's Objections to Exhibits Download | |
| Oct 20, 2017 | 14 | Petitioner's Request for Rehearing Pursuant to 37 C.F.R. ¿¿ 42.71(c) and (d) Download | |
| Oct 6, 2017 | 12 | Trial Instituted Document Download | |
| Oct 6, 2017 | 13 | Scheduling Order Download | |
| Jul 10, 2017 | 2001 | Ex. 2001 Al-Ismail 1987 Download | |
| Jul 10, 2017 | 2009 | Ex. 2009 Carlson 1997 Download | |
| Jul 10, 2017 | 2006 | Ex. 2006 Amendment and Reply (August 25, 2010) Download | |
| Jul 10, 2017 | 2011 | Ex. 2011 Song Declaration Download | |
| Jul 10, 2017 | 2003 | Ex. 2003 Application No. 11_840,956 Download | |
| Jul 10, 2017 | 11 | Patent Owner's Exhibit List Download | |
| Jul 10, 2017 | 2008 | Ex. 2008 Reply and Amendment (Sept 14, 2001) Download | |
| Jul 10, 2017 | 2004 | Ex. 2004 U.S. Patent No. 8,329,172 Download | |
| Jul 10, 2017 | 2010 | Ex. 2010 Prior 172 IPR Board Decision Download | |
| Jul 10, 2017 | 2002 | Ex. 2002 McLaughlin 1998 Download | |
| Jul 10, 2017 | 2007 | Ex. 2007 Amendment and Reply (June 6, 2011) Download | |
| Jul 10, 2017 | 2005 | Ex. 2005 Application No. 10_196,732 Download | |
| Jul 10, 2017 | 10 | Biogen's Patent Owner Preliminary Response Download | |
| Apr 14, 2017 | 9 | NOTICE OF ACCEPTING CORRECTED PETITION Download | |
| Apr 12, 2017 | 8 | Notice of Corrected Exhibits Download | |
| Apr 12, 2017 | 1061 | (Corrected) Cabanillas, F. et al., Anti-CD20 Antibody (MAB), IDEC-C2B8: Clearance of Bcl-2 t(14:18) Positive Cells from Peripheral Blood (PB) and Bone Marrow (BM) in Patients (PTS) with Relapsed Low-Grade or Follicular Lymphoma (LG/F NHL), Blood, 1996; 88 Download | |
| Apr 12, 2017 | 1061 | (Corrected) Cabanillas, F. et al., Anti-CD20 Antibody (MAB), IDEC-C2B8: Clearance of Bcl-2 t(14:18) Positive Cells from Peripheral Blood (PB) and Bone Marrow (BM) in Patients (PTS) with Relapsed Low-Grade or Follicular Lymphoma (LG/F NHL), Blood, 1996; 88 Download | |
| Apr 12, 2017 | 1008 | (Corrected) Foon, K.A. & Fisher, R.I., Chapter 111: Lymphomas, in Williams Hematology, Fifth Edition, 1076-96 (Beutler, E. et al., eds., 1995) Download | |
| Apr 12, 2017 | 1011 | (Corrected) Czuczman, M.S. et al., IDEC-C2B8 and CHOP Chemoimmunotherapy of Low-Grade Lymphoma, Blood 86(10, Supp. 1):55a (Abstract 206) (Nov. 15, 1995) ("Czuczman No. 1996") Download | |
| Apr 12, 2017 | 1006 | (Corrected ) IDEC Pharmaceuticals Corporation, Form 10-K/A for the Fiscal Year ended December 31, 1997, filed with the U.S. Securities and Exchange Commission Download | |
| Apr 12, 2017 | 1007 | (Corrected) U.S. Patent No. 5,736,137 ("the '137 Patent") Download | |
| Apr 12, 2017 | 1017 | (Corrected) Czuczman, M. et al., Phase II Clinical Trial of IDEC-C2B8/CHOP Combination Chemotherapy in Low Grade Lymphoma: Preliminary Results, Program/Proceedings Am. Soc. Clin. Oncol., 14:401 (Abstract 1261) (Apr. 1995) Download | |
| Apr 12, 2017 | 1034 | (Corrected) File History of U.S. Patent Application No. 09/372,202 ("the '202 application") Download | |
| Apr 12, 2017 | 1034 | (Corrected) File History of U.S. Patent Application No. 09/372,202 ("the '202 application") Download | |
| Apr 12, 2017 | 1017 | (Corrected) Czuczman, M. et al., Phase II Clinical Trial of IDEC-C2B8/CHOP Combination Chemotherapy in Low Grade Lymphoma: Preliminary Results, Program/Proceedings Am. Soc. Clin. Oncol., 14:401 (Abstract 1261) (Apr. 1995) Download | |
| Apr 12, 2017 | 1008 | (Corrected) Foon, K.A. & Fisher, R.I., Chapter 111: Lymphomas, in Williams Hematology, Fifth Edition, 1076-96 (Beutler, E. et al., eds., 1995) Download | |
| Apr 12, 2017 | 1011 | (Corrected) Czuczman, M.S. et al., IDEC-C2B8 and CHOP Chemoimmunotherapy of Low-Grade Lymphoma, Blood 86(10, Supp. 1):55a (Abstract 206) (Nov. 15, 1995) ("Czuczman No. 1996") Download | |
| Apr 12, 2017 | 1006 | (Corrected ) IDEC Pharmaceuticals Corporation, Form 10-K/A for the Fiscal Year ended December 31, 1997, filed with the U.S. Securities and Exchange Commission Download | |
| Apr 12, 2017 | 1007 | (Corrected) U.S. Patent No. 5,736,137 ("the '137 Patent") Download | |
| Apr 12, 2017 | 1009 | (Corrected) Dana, B. et al., Long-Term Follow-Up of Patients With Low-Grade Malignant Lymphomas Treated With Doxorubicin-Based Chemotherapy or Chemoimmunotherapy, J. Clin. Oncol., 11(4):644-651 (Apr. 1993) Download | |
| Apr 12, 2017 | 1010 | (Corrected) Link, B.K. et al., Phase II Pilot Study of the Safety and Efficacy of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Intermediate- or High-Grade NHL, Program/Proceedings Am. Soc. Clin. Oncol., 17:3a Download | |
| Apr 12, 2017 | 1012 | (Corrected) U.S. Patent No. 6,399,061 ("the '061 Patent") Download | |
| Apr 12, 2017 | 1030 | (Corrected) Sriskandan, S. et al., Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin, Postgrad. Med. J., 70(828):759-761 (Oct. 1994) Download | |
| Apr 12, 2017 | 1064 | (Corrected) Grossbard, M.L. and Multani, P.S., The McLaughlin, et al. Article [Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas] Reviewed, Oncology, 12(12):1769-1781 (Dec. 1, 1998) Download | |
| Apr 12, 2017 | 1069 | (Corrected) File History of U.S. Patent Application No. 13/524,896 ("the '896 application") Download | |
| Apr 10, 2017 | 7 | Notice of Accord Filing Date Download | |
| Apr 5, 2017 | 5 | Power of Attorney Download | |
| Apr 5, 2017 | 6 | Mandatory Notice Download | |
| Mar 17, 2017 | 4 | Petitioner's Updated Mandatory Notice re Lead Backup Counsel Download | |
| Mar 17, 2017 | 3 | Certificate of Service re corrected exhibits Download | |
| Mar 17, 2017 | 1003 | Longo Declaration (Corrected) Download | |
| Mar 17, 2017 | 1002 | Lossos Declaration (Corrected) Download | |
| Mar 17, 2017 | 1002 | Lossos Declaration (Corrected) Download | |
| Mar 17, 2017 | 1003 | Longo Declaration (Corrected) Download | |
| Mar 15, 2017 | 1071 | ECOG Protocols Active as of 05/19/98 Download | |
| Mar 15, 2017 | 1078 | Demiden, A. et al., Chimeric Anti-CD20 Antibody (IDEC-C2B8) Is Apoptotic and Sensitizes Drug Resistant Human B Cell Lymphomas and Aids Related Lymphomas to the Cytotoxic Effect of CDDP, VP-16 and Toxins, Experimental Biology 95™ Download | |
| Mar 15, 2017 | 1051 | IDEC Pharmaceuticals Corporation Press Release, IDEC Pharmaceuticals and Genentech Announce Positive Final Results for Pivotal Phase III Trial of IDEC-C2B8 as Single Agent (Dec. 9, 1996) Download | |
| Mar 15, 2017 | 1055 | EDGAR® FILER MANUAL: Guide for Electronic Filing with the U.S. Securities and Exchange Commission, EDGAR® Release 5.10 (Sept. 1996) [excerpts] Download | |
| Mar 15, 2017 | 1080 | Haq, M.M. et al., Doxorubicin-Induced Congestive Heart Failure in Adults, Cancer, 56(6):1361-1365 (Sept. 15, 1985) Download | |
| Mar 15, 2017 | 1069 | File History of U.S. Patent Application No. 13/524,896 ("the '896 application") Download | |
| Mar 15, 2017 | 1060 | Rituxan (Rituximab) label (Feb. 28, 2006) Download | |
| Mar 15, 2017 | 1075 | E1496 On Study Dates Download | |
| Mar 15, 2017 | 1058 | FDA FOIA response letter dated August 26, 2016 Download | |
| Mar 15, 2017 | 1053 | Smith, M.R., Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance, Oncogene, 22(47):7359-7368 (Oct. 20, 2003) Download | |
| Mar 15, 2017 | 1049 | Czuczman, M. et al., RituxanTM/CHOP Chemo Immunotherapy in Patients with Low-Grade or Follicular (LG/F) Non-Hodgkin's Lymphoma (NHL), J. Immunother., 20(5):401 (1997) Download | |
| Mar 15, 2017 | 1057 | Public Hearing Transcript, Biological Response Modifiers Advisory Committee, Center for Biological Evaluation and Research, Food and Drug Administration, nineteenth meeting (July 25, 1997) ("FDA Transcript") Download | |
| Mar 15, 2017 | 1074 | E1496 Forms Packet Download | |
| Mar 15, 2017 | 1079 | Demidem A. et al., Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs, Cancer Biother. Radio., 12(3):177-186 (1997) Download | |
| Mar 15, 2017 | 1065 | Eastern Cooperative Oncology Group ("ECOG") E1496 Protocol (1998) Download | |
| Mar 15, 2017 | 2 | Petition for Inter Partes Review of U.S. Patent No. 9,296,821 Download | |
| Mar 15, 2017 | 1070 | Ruuls, S.R. et al., Novel human antibody therapeutics: the age of the Umabs, Biotechnol. J., 3:1157-1171 (2008) Download | |
| Mar 15, 2017 | 1056 | Attachment 2: IDEC Pharmaceuticals Filing Details on the EDGAR system, available at https://www.sec.gov/Archives/edgar/data/875045/ 0000936392-98-000361-index.html Download | |
| Mar 15, 2017 | 1068 | O'Brien, S. et al., Lack of Effect of 2-Chlorodeoxyadenosine Therapy in Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine Therapy, New Engl. J. Med. 330(5):319-322 (Feb. 3, 1994) Download | |
| Mar 15, 2017 | 1050 | Czuczman, M.S. et al., IDEC-C2B8 (Rituximab) Alone and in Combination with CHOP in the Treatment of Low-Grade B-Cell Lymphoma, Cancer Invest., 16 (Suppl. 1):21-22 (Abstract 17) (1998) Download | |
| Mar 15, 2017 | 1059 | McNeil, C., Non-Hodgkin's Lymphoma Trials In Elderly Look Beyond CHOP, J. Nat'l Cancer Inst., 90(4):266-67 (Feb. 18, 1998) ("McNeil") Download | |
| Mar 15, 2017 | 1081 | Harris, N.L. et al., A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group, Blood, 84(5):1361-1392 (Sept. 1, 1994) Download | |
| Mar 15, 2017 | 1066 | ECOG E1496 Patient Consent Form Download | |
| Mar 15, 2017 | 1054 | Maloney, D.G. et al., Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients With Recurrent B-Cell Lymphoma, Blood, 84(8):2457-2466 (Oct. 15, 1994) ("Maloney 1994") Download | |
| Mar 15, 2017 | 1069 | File History of U.S. Patent Application No. 13/524,896 ("the '896 application") Download | |
| Mar 15, 2017 | 1064 | Grossbard, M.L. and Multani, P.S., The McLaughlin, et al. Article [Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas] Reviewed, Oncology, 12(12):1769-1781 (Dec. 1, 1998) Download | |
| Mar 15, 2017 | 1064 | Grossbard, M.L. and Multani, P.S., The McLaughlin, et al. Article [Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas] Reviewed, Oncology, 12(12):1769-1781 (Dec. 1, 1998) Download | |
| Mar 15, 2017 | 1048 | Czuczman, M. et al., IDEC-C2B8 clears bcl2 (t14;18) in patients (pts) with relapsed low grade or follicular lymphoma (LG/F NHL), P. Am. Assoc. Canc. Res., 38:84 (Abstract 565) (Mar. 1997) Download | |
| Mar 15, 2017 | 1027 | Maloney, D.G. et al., IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma, Blood, 90(6): 2188-2195 (Sept. 15, 1997) Download | |
| Mar 15, 2017 | 1028 | Czuczman, M.S., et al., Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up, J. Clin. Oncol., 22(23):4711-4716 (Dec. 1, 2004) Download | |
| Mar 15, 2017 | 1021 | Leget, G.A. et al., Use of rituximab, the new FDA-approved antibody, Curr. Opin. Oncol. 10(6):548-551 (Nov. 1998) Download | |
| Mar 15, 2017 | 1 | Petitioner's Power of Attorney Download | |
| Mar 15, 2017 | 1033 | Berinstein, N.L., et al., Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, Ann. Oncol., 9:995-1001 (July 1998) Download | |
| Mar 15, 2017 | 1031 | Steward, W.P. et al., Maintenance Chlorambucil After CVP in the Management of Advanced Stage, Low-Grade Histologic Type Non-Hodgkin's Lymphoma: A Randomized Prospective Study With an Assessment of Prognostic Factors, Cancer 61(3):441-447 (Feb. 1, 1988) Download | |
| Mar 15, 2017 | 1038 | Rogers, J. et al., Analysis of bcl-2 t(14;18) translocation in relapsed B-cell lymphoma patients treated with the chimeric anti-CD20 antibody IDEC-C2B8, P. Am. Assoc. Canc. Res., 37:213 (Abstract 1456) (Mar. 1996) Download | |
| Mar 15, 2017 | 1018 | Devita, V. T., Jr. et al., Chapter 44: Hodgkin's Disease and the Non-Hodgkin's Lymphomas, in Cancer: Principles & Practice of Oncology, Second Edition (DeVita, Jr. et al., eds., 1985) Download | |
| Mar 15, 2017 | 1001 | U.S. Patent No. 9,296,821 ("the '821 patent") Download | |
| Mar 15, 2017 | 1044 | Hoppe, T.E. et al., The Treatment of Advanced Stage Favorable Histology Non-Hodgkin's Lymphoma: A Preliminary Report of a Randomized Trial Comparing Single Agent Chemotherapy, Combination Chemotherapy, and Whole Body Irradiation, Download | |
| Mar 15, 2017 | 1019 | Rituxan (Rituximab) label (Nov. 1997) Download | |
| Mar 15, 2017 | 1005 | Marcus, R. et al., CVP Chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, 105(4):1417-1423 (Feb. 15, 2005) ("Marcus 2005") Download | |
| Mar 15, 2017 | 1004 | Piro, L. et al., RITUXAN™ (rituximab, IDEC-C2B8): Interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma, Blood 90(10, Supp. 1):510a (Abstract 2272) (Nov. 15, 1997) Download | |
| Mar 15, 2017 | 1047 | Kimby, E. et al., Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden, Ann. Oncol., 5(Supp. 2):67-71 (1994) Download | |
| Mar 15, 2017 | 1024 | Coiffier B., et al., Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study, Blood, 92(6):1927-1932 (Sept. 15, 1998) Download | |
| Mar 15, 2017 | 1016 | Reff, M.E. et al., Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20, Blood, 83(2):435-445 (Jan. 15, 1994) ("Reff 1994") Download | |
| Mar 15, 2017 | 1014 | Stashenko, P. et al., Characterization of a Human B Lymphocyte-Specific Antigen, J. Immunol., 125(4):1678-1685 (Oct. 1980) ("Stashenko 1980") Download | |
| Mar 15, 2017 | 1022 | Maloney, D.G. and Press, O.W., Newer Treatments for Non-Hodgkin's Lymphoma: Monoclonal Antibodies, Oncology 12(10, Supp. 8):63-76 (Oct. 1998) Download | |
| Mar 15, 2017 | 1039 | Czuczman, M.S. et al., IDEC-C2B8/CHOP chemoimmunotherapy in patients with low-grade lymphoma: interim clinical and bcl-2 (PCR) results, Ann. Oncol., 7(Supp. 1):56 (Abstract 191) (1996) Download | |
| Mar 15, 2017 | 1045 | Canellos, G.P. et al., Chemotherapy of the Non-Hodgkin's Lymphomas, Cancer, 42(2):932-940 (Aug. 1978) Download | |
| Mar 15, 2017 | 1046 | Rosenberg, S.A., The Low-Grade Non-Hodgkin's Lymphomas: Challenges and Opportunities, J. Clin. Oncol., 3(3):299-310 (Mar. 1985) Download | |
| Mar 15, 2017 | 1013 | Nadler, L.M. et al., Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen, Cancer Res., 40(9):3147-3154 (Sept. 1980) ("Nadler 1980") Download | |
| Mar 15, 2017 | 1015 | Anderson, K.C. et al., Expression of Human B Cell-Associated Antigens on Leukemias and Lymphomas: A model of Human B Cell Differentiation, Blood, 63(6):1424-1433 (June 1984) (Anderson 1984) Download | |
| Mar 15, 2017 | 1020 | Czuczman, M.S. et al, Treatment of patients with Low-grade B-Cell Lymphoma with the Combination of Chimeric Anti-20 Monoclonal Antibody and CHOP Chemotherapy, J. Clin. Oncol. 17(1):268-276 (Jan. 1999) ("Czuczman 1999") Download | |
| Mar 15, 2017 | 1032 | Maloney, D.G. et al., IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients With Relapsed Non-Hodgkin's Lymphoma, J. Clin. Oncol., 15(10):3266-3274 (Oct. 1997) Download | |
| Mar 15, 2017 | 1043 | Czuczman, M. et al., IDEC-C2B8/CHOP Chemoimmunotherapy in Patients with Low-Grade Lymphoma: Clinical and bcl-2 (PCR) Final Results, Blood, 88(10, Supp. 1):453a (Abstract 1799) (Nov. 15, 1996) Download | |
| Mar 15, 2017 | 1025 | Horning S., Treatment Approaches to the Low-Grade Lymphomas, Blood 83(4):881-884 (Feb. 15, 1994) Download | |
| Mar 15, 2017 | 1036 | Bishop, J.F. et al., A Randomized Trial of High Dose Cyclophosphamide, Vincristine, and Prednisone Plus or Minus Doxorubicin (CVP versus CAVP) with Long-Term Follow-Up in Advanced Non-Hodgkin's Lymphoma, Leukemia, 1(6):508-513 (June 1987) Download | |
| Mar 15, 2017 | 1041 | Czuczman, M.S. et al., Chemoimmunotherapy of Low-Grade Lymphoma with Anti-CD20 Antibody IDEC-C2B8 in Combination with CHOP Chemotherapy, Cancer Invest., 14(Supp. 1):59-61 (Abstract 53) (1996) Download | |
| Mar 15, 2017 | 1012 | U.S. Patent No. 6,399,061 ("the '061 Patent") Download | |
| Mar 15, 2017 | 1009 | Dana, B. et al., Long-Term Follow-Up of Patients With Low-Grade Malignant Lymphomas Treated With Doxorubicin-Based Chemotherapy or Chemoimmunotherapy, J. Clin. Oncol., 11(4):644-651 (Apr. 1993) Download | |
| Mar 15, 2017 | 1030 | Sriskandan, S. et al., Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin, Postgrad. Med. J., 70(828):759-761 (Oct. 1994) Download | |
| Mar 15, 2017 | 1010 | Link, B.K. et al., Phase II Pilot Study of the Safety and Efficacy of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Intermediate- or High-Grade NHL, Program/Proceedings Am. Download | |
| Mar 15, 2017 | 1012 | U.S. Patent No. 6,399,061 ("the '061 Patent") Download | |
| Mar 15, 2017 | 1010 | Link, B.K. et al., Phase II Pilot Study of the Safety and Efficacy of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Intermediate- or High-Grade NHL, Program/Proceedings Am. Download | |
| Mar 15, 2017 | 1030 | Sriskandan, S. et al., Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin, Postgrad. Med. J., 70(828):759-761 (Oct. 1994) Download | |
| Mar 15, 2017 | 1009 | Dana, B. et al., Long-Term Follow-Up of Patients With Low-Grade Malignant Lymphomas Treated With Doxorubicin-Based Chemotherapy or Chemoimmunotherapy, J. Clin. Oncol., 11(4):644-651 (Apr. 1993) Download | |
| Mar 15, 2017 | 1002 | Expert Declaration of Dr. Izidore Lossos Download | |
| Mar 15, 2017 | 1003 | Declaration of Walter Longo, MD Download | |
| Mar 15, 2017 | 1006 | IDEC Pharmaceuticals Corporation, Form 10-K/A for the Fiscal Year ended December 31, 1997, filed with the U.S. Securities and Exchange Commission Download | |
| Mar 15, 2017 | 1007 | U.S. Patent No. 5,736,137 ("the '137 Patent") Download | |
| Mar 15, 2017 | 1008 | Foon, K.A. & Fisher, R.I., Chapter 111: Lymphomas, in Williams Hematology, Fifth Edition, 1076-96 (Beutler, E. et al., eds., 1995) Download | |
| Mar 15, 2017 | 1011 | Czuczman, M.S. et al., IDEC-C2B8 and CHOP Chemoimmunotherapy of Low-Grade Lymphoma, Blood 86(10, Supp. 1):55a (Abstract 206) (Nov. 15, 1995) ("Czuczman Nov. 1995") Download | |
| Mar 15, 2017 | 1017 | Czuczman, M. et al., Phase II Clinical Trial of IDEC-C2B8/CHOP Combination Chemotherapy in Low Grade Lymphoma: Preliminary Results, Program/Proceedings Am. Soc. Clin. Oncol., 14:401 (Abstract 1261) (Apr. 1995) ("Czuczman April 1995") Download | |
| Mar 15, 2017 | 1034 | File History of U.S. Patent Application No. 09/372,202 ('the '202 application") Download | |
| Mar 15, 2017 | 1061 | Cabanillas, F. et al., Anti-CD20 Antibody (MAB), IDEC-C2B8: Clearance of Bcl-2 t(14:18) Positive Cells from Peripheral Blood (PB) and Bone Marrow (BM) in Patients (PTS) with Relapsed Low-Grade or Follicular Lymphoma (LG/F NHL) Download |
